P/B
1,4
Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
$115.6B
Market Cap • 11/10/2026
1994
(32 years)
Founded
2002
(24 years ago)
IPO
NASDAQ
Listing Exchange
France
Country
Valuation
P/S
2
P/EBITDA
11,7
P/OCF
8,4
P/FCF
8,4
P/E
24,3
BVPS
34,5
EPS
2
Market Cap
Market Cap
115,6B
EV
131,7B
EV/Revenue
2,2
EV/EBITDA
13,3
EV/EBIT
17,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Dividend Yield 5Y
1,1%
Payout
0%
Profitability
Gross Margin
73,4%
EBITDA Margin
16,8%
EBIT Margin
12,6%
Net Margin
8,1%
D&A/EBITDA
25,4%
R&D/Revenue
16%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
9,3%
% Goodwill
0%
ROE
5,6%
ROIC
4,4%
Growth
CAGR Revenue 5Y
5,4%
CAGR Op. Income 5Y
-5,2%
CAGR Net Income 5Y
-8,2%
CAGR EPS 5Y
-7,3%
CAGR OCF 5Y
6,5%
Leverage
N.D./EBITDA
1,6
Debt/Equity
0%
Current Ratio
1,1
Quick Ratio
0,2
Interest Coverage
973,7%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!